The proceeds from the development and commercialization of Ziihera, Pasritamig, among others, will be reinvested in the ...

Dubai, United Arab Emirates: A new chapter in the UAE’s technological future begins today with the official opening of the AI ...

In order to have the flexibility to opportunistically allocate excess capital to share repurchases, today the Company announced that its Board of Directors has authorized a new share repurchase plan ...

Q3 2025 Management View Matthew Duffy, Chief Business Officer & Co-CEO of Hope Therapeutics, opened the call stating, "Since the beginning of the third quarter, NRx has made transformative progress in ...

EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) ("EnviroGold" or the "Company") is pleased to announce the publication of ...

PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...

For decades, fusion energy was often seen as a concept from science fiction—a promise that seemed forever on the horizon.

The FDA has granted full approval to Kura Oncology and Kyowa Kirin’s Komzifti (ziftomenib), marking the first FDA-approved once-daily, oral menin inhibitor for adults with relapsed or refractory (R/R) ...

HIGHLIGHTS Conference Call Information The Company will hold a conference call to discuss its financial results for the second quarter of 2025 at 8:30 a.m. ET on Friday, November 14, 2025.

COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3 2024.